See more : BankInvest Lange Danske Obligationer (BAILDOBA.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Verastem, Inc. (VSTM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Verastem, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Aspira Pathlab & Diagnostics Limited (ASPIRA.BO) Income Statement Analysis – Financial Results
- Delic Holdings Corp. (DELC.CN) Income Statement Analysis – Financial Results
- Gas2Grid Limited (GGX.AX) Income Statement Analysis – Financial Results
- Bengal & Assam Company Limited (BENGALASM.BO) Income Statement Analysis – Financial Results
- KMA Holding, Inc. (MCDA) Income Statement Analysis – Financial Results
Verastem, Inc. (VSTM)
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 2.60M | 2.05M | 88.52M | 17.46M | 26.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 62.00K | 118.00K | 206.00K | 33.75M | 2.81M | 165.00K | 556.00K | 670.00K | 754.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -62.00K | 2.48M | 1.85M | 54.77M | 14.65M | 26.55M | -556.00K | -670.00K | -754.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 95.45% | 89.97% | 61.88% | 83.92% | 99.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 61.36M | 50.56M | 39.35M | 41.38M | 45.78M | 43.65M | 46.42M | 19.78M | 40.57M | 35.45M | 25.93M | 21.71M | 9.88M | 400.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 77.27M | 21.38M | 17.22M | 17.63M | 18.16M | 15.47M | 10.52M | 3.82M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.67M | 24.98M | 24.12M | 62.76M | 101.21M | 77.27M | 21.38M | 17.22M | 17.63M | 18.16M | 15.47M | 10.52M | 3.82M | 576.00K |
| Other Expenses | 0.00 | 47.00K | 0.00 | -1.31M | -641.00K | 423.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -288.00K |
| Operating Expenses | 92.02M | 75.53M | 63.46M | 104.13M | 146.99M | 121.34M | 67.80M | 37.00M | 58.20M | 53.61M | 41.40M | 32.23M | 13.70M | 688.00K |
| Cost & Expenses | 92.08M | 75.53M | 63.46M | 137.88M | 149.80M | 121.50M | 67.80M | 37.00M | 58.20M | 53.61M | 41.40M | 32.23M | 13.70M | 688.00K |
| Interest Income | 6.21M | 1.22M | 181.00K | 515.00K | 4.38M | 2.60M | 561.00K | 562.00K | 334.00K | 242.00K | 200.00K | 246.00K | 15.00K | 0.00 |
| Interest Expense | 4.14M | 2.14M | 9.97M | 15.79M | 20.61M | 5.81M | 559.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 62.00K | 118.00K | 206.00K | 1.32M | 2.00M | 1.42M | 556.00K | 670.00K | 754.00K | 427.00K | 236.00K | 207.00K | 83.00K | 0.00 |
| EBITDA | -83.17M | -71.56M | -61.02M | -50.41M | -126.60M | -65.21M | -66.69M | -35.77M | -57.11M | -52.94M | -40.97M | -31.78M | -13.62M | -784.00K |
| EBITDA Ratio | 0.00% | -2,760.98% | -2,982.37% | -53.76% | -724.23% | -339.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -92.08M | -72.94M | -61.41M | -49.36M | -132.34M | -94.78M | -67.80M | -37.00M | -58.20M | -53.61M | -41.40M | -32.23M | -13.70M | -784.00K |
| Operating Income Ratio | 0.00% | -2,809.59% | -2,991.18% | -55.76% | -758.14% | -354.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.72M | -875.00K | -9.79M | -18.17M | -16.87M | 22.35M | 2.00K | 562.00K | 334.00K | 242.00K | 200.00K | 246.00K | 15.00K | 0.00 |
| Income Before Tax | -87.37M | -73.81M | -71.20M | -67.53M | -149.21M | -72.43M | -67.80M | -36.44M | -57.87M | -53.37M | -41.20M | -31.98M | -13.68M | -784.00K |
| Income Before Tax Ratio | 0.00% | -2,843.30% | -3,468.10% | -76.29% | -854.77% | -271.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 36.00K | 9.90M | 194.00K | 19.97M | 28.16M | 561.00K | 0.00 | -754.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -87.37M | -73.85M | -81.10M | -67.73M | -169.18M | -72.43M | -67.80M | -36.44M | -57.87M | -53.37M | -41.20M | -31.98M | -13.68M | -786.00K |
| Net Income Ratio | 0.00% | -2,844.68% | -3,950.32% | -76.51% | -969.16% | -271.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.96 | -4.58 | -5.58 | -5.30 | -27.22 | -12.54 | -21.18 | -11.82 | -19.32 | -24.82 | -21.80 | -20.45 | -8.11 | -0.53 |
| EPS Diluted | -3.96 | -4.58 | -5.58 | -5.30 | -27.22 | -12.54 | -21.18 | -11.82 | -19.32 | -24.82 | -21.80 | -20.45 | -8.11 | -0.53 |
| Weighted Avg Shares Out | 22.05M | 16.14M | 14.53M | 12.78M | 6.21M | 5.78M | 3.20M | 3.08M | 2.99M | 2.15M | 1.89M | 1.56M | 1.69M | 1.47M |
| Weighted Avg Shares Out (Dil) | 22.05M | 16.14M | 14.53M | 12.78M | 6.21M | 5.78M | 3.20M | 3.08M | 2.99M | 2.15M | 1.89M | 1.56M | 1.69M | 1.47M |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
Verastem: A Shocking Drop On 'Positive' Data (Maintain Buy)
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
Verastem opened 70% down on Friday: what happened?
Why Is Verastem (VSTM) Stock Down 62% Today?
Harvest ETFs announces May 2024 Distributions
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Verastem shares surge more than 50% after pancreatic-cancer treatment study data
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports